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Abstract
Objective The aim was to test the hypothesis that preoperative infusion of levosimendan would decrease patients’ cardiac 
biomarker profiles during the immediate postoperative stage (troponin I and B-type natriuretic peptide levels) more efficiently 
than placebo after cardiopulmonary bypass.
Methods In a randomised, placebo-controlled, double-blinded study, 30 paediatric patients were scheduled for congenital 
heart disease surgery. 15 patients (50%) received prophylactic levosimendan and 15 patients (50%) received placebo from 
12 h before cardiopulmonary bypass to 24 h after surgery.
Results Troponin I levels were higher in the placebo group at 0, 12, and 24 h after cardiopulmonary bypass, although the 
mean differences between the study groups and the 95% confidence intervals (CIs) for troponin I levels did not present statisti-
cally significant differences at any of the three time points considered (mean differences [95% CIs] − 3.32 pg/ml [− 19.34 to 
12.70], − 2.42 pg/ml [− 19.78 to 13.95], and − 79.94 pg/ml [− 266.99 to 16.39] at 0, 12, and 24 h, respectively). A similar 
lack of statistically significant difference was observed for B-type natriuretic peptide (mean differences [95% CIs] 36.86 
pg/dl [− 134.16 to 225.64], − 350.79 pg/dl [− 1459.67 to 557.45], and − 310.35 pg/dl [− 1505.76 to 509.82]). Lactic acid 
levels were significantly lower with levosimendan; the mean differences between the study groups and the 95% CIs for lactate 
levels present statistically significant differences at 0 h (− 1.52 mmol/l [− 3.19 to − 0.25]) and 12 h (− 1.20 mmol/l [− 2.53 
to − 0.10]) after cardiopulmonary bypass. Oxygen delivery  (DO2) was significantly higher at 12 h and 24 h after surgery 
(mean difference [95% CI] 627.70 ml/min/m2 [122.34–1162.67] and 832.35 ml/min/m2 [58.15 to 1651.38], respectively).
Conclusions Levosimendan does not significantly improve patients’ postoperative troponin I and B-type natriuretic peptide 
profiles during the immediate postoperative stage in comparison with placebo, although both were numerically higher with 
placebo. Levosimendan, however, significantly reduced lactic acid levels and improved patients’  DO2 profiles. These results 
highlight the importance of this new drug and its possible benefit with regard to myocardial injury; however, evaluation in 
larger, adequately powered trials is needed to determine the efficacy of levosimendan.
Trial registry number: EudraCT 2012-005310-19.
 * Jose M. Gómez-Luque 
 pepegomezluque@gmail.com
1 Pediatric Intensive Care Unit, Hospital Universitario Virgen 
de las Nieves, University of Granada, Granada, Spain
2 Paediatric Cardiology Unit, Hospital Universitario Virgen de 
las Nieves, Granada, Spain
3 Paediatric Cardiac Surgery Unit, Hospital Universitario 
Virgen de las Nieves, Granada, Spain
4 Pediatric Anesthesia Unit, Hospital Universitario Virgen de 
las Nieves, Granada, Spain
1 Introduction
Low cardiac output syndrome in children is mainly asso-
ciated with congenital heart disease, cardiomyopathy, or 
sepsis. After cardiac surgery, its incidence is nearly 25% 
[1]. Risk factors in this context are related to the patient’s 
preoperative condition, age, type of surgery (corrective 
or palliative), and duration of aortic clamping, changes in 
pulmonary and systemic vascular resistance, cardioplegia, 
and the activation or otherwise of systemic inflammatory 
response syndrome due to extracorporeal circulation. These 
factors can induce the appearance of ventricular dysfunction 
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Key Points 
A randomised controlled trial was conducted to test the 
hypothesis that preoperative infusion of levosimendan 
would decrease myocardial injury biomarkers (troponin 
I and B-type natriuretic peptide) after paediatric cardiac 
surgery more efficiently than placebo.
Troponin I and B-type natriuretic peptide levels were 
higher with placebo at 12 and 24 h after cardiopulmo-
nary bypass, but the differences were not statistically 
significant. Lactic acid level was significantly lower and 
oxygen delivery  (DO2) was significantly higher at 12 and 
24 h after surgery in Levosimendan group.
The results highlight the importance of this new drug 
and its possible benefit with regard to myocardial injury; 
however, evaluation in larger, adequately powered trials 
is needed to determine the efficacy of levosimendan.
secondary to myocardial ischaemia and an acute inflamma-
tory response [2].
For these patients, the occurrence of heart failure in the 
immediate postoperative phase produces a considerable 
increase in morbidity and mortality, due to the longer period 
of mechanical ventilation required and the longer stay in an 
intensive care unit mainly. Therefore, the early treatment 
(and ideally, prevention) is an essential objective in the sur-
gical intervention performed [3].
The current protocols for treating heart failure include 
the administration of catecholamines, milrinone, and, more 
recently, levosimendan [4]. Unlike the situation in adult 
patients, cardiac output monitoring in children is a complex 
matter; validated echocardiographic parameters have not yet 
been established and treatment is fundamentally based on 
clinical evaluation and the monitoring of parameters such 
as lactate levels, diuresis, central venous oxygen saturation, 
cerebral near-infrared spectroscopy (NIRS), laboratory 
parameters of end organ function, and haemodynamic pres-
sures [2, 5].
The standard treatment of low cardiac output with ino-
tropic drugs heightens contractility by increasing cyclic 
adenosine monophosphate (cAMP) and free intracellular 
calcium, which in turn increases oxygen consumption and 
raises the risk of arrhythmia and cell death [6]. Levosi-
mendan belongs to a new category of inotropic drugs termed 
calcium sensitisers, which improve myocardial contractility 
by increasing the sensitivity of myofibrils to calcium dur-
ing systole, thus achieving greater inotropic power without 
increasing the concentration of intracellular calcium, in con-
trast to alternative inotropic drugs. As a consequence, there 
is no increase in myocardial oxygen consumption, which 
is the main disadvantage of other inotropic drugs. Levosi-
mendan, unlike milrinone, does not progressively increase 
intracellular calcium levels and therefore does not aggravate 
the risk of arrhythmia [7] or produce other effects associated 
with increased intracellular calcium, such as cell death, sys-
tolic and/or diastolic dysfunction, or increased consumption 
of oxygen by myocytes [8, 9]. In addition, levosimendan 
exerts a cardioprotective effect on the cardiac muscle by 
opening the mitochondrial potassium channels of the car-
diomyocyte. These features mean that levosimendan has a 
cardioprotective effect and, from a theoretical standpoint, 
makes an ideal drug for the management of low cardiac out-
put [9–11]. Levosimendan does not provoke any increase in 
myocardial oxygen consumption, due to its combined vaso-
dilatory effect, which reduces the afterload. This effect is 
responsible for its myocardial anti-ischaemic action, thus 
improving the stunned myocardium function, preventing 
myocardial apoptosis and stimulating a pre-ischaemic myo-
cardial conditioner [12–17]. The haemodynamic effects of 
levosimendan are greatest in the first 72 h after adminis-
tration and persist for at least 7 days after the infusion is 
concluded [18]. Mindful of these cardioprotective effects, 
the present study was designed to evaluate the efficacy of 
levosimendan in the pre-ischaemic myocardial conditioning 
of paediatric patients considered at high risk of suffering low 
cardiac output in the immediate postoperative period.
This study, therefore, tests the hypothesis that levosi-
mendan infusion, when started in the preoperative stage of 
congenital heart disease surgery, could prevent postopera-
tive myocardial dysfunction in children. The primary study 
aim was to study the effect of levosimendan versus placebo 
treatment, administered during the preoperative stage of 
congenital heart disease surgery, on troponin I and B-type 
natriuretic peptide (BNP), biomarkers of myocardial injury, 
during the immediate postoperative period.
2  Methods
The study was approved by the Andalusian Regional Eth-
ics Committee (code: EudraCT 2012-005310-19; date of 
approval, 12 December 2012). Signed informed consent 
was obtained from the parents/guardians of all the partici-
pants. This randomised, phase III, double-blind, placebo-
controlled clinical trial was conducted in a single hospital 
(Virgen de las Nieves University Hospital, Granada, Spain). 
The participants, aged between 28 days and 13 years, were 
randomised in a 1:1 procedure into two groups. The inter-
vention was masked from the investigator, the nursing staff, 
and the patients. Two intervention branches were analysed: 
levosimendan versus placebo. The duration of the treatment 
phase was 36 h.
Levosimendan’s Effect on Biomarkers of Myocardial Injury After Paediatric Cardiac Surgery
2.1  Inclusion and Exclusion Criteria
All patients were transferred from the operation room to the 
paediatric intensive care unit (PICU) in Virgen de las Nieves 
University Hospital in Granada, Spain. Patients were aged 
between 28 days and 13 years, and were scheduled for car-
diopulmonary bypass. The patients needed to have at least 
two of the following risk factors for developing low cardiac 
output after surgery:
• Aged less than 6 months or weighing less than 7 kg at the 
time of surgery
• Heart failure before the surgery (defined as clinical stage 
III–IV according to the modified Ross Classification of 
cardiac insufficiency in children [19])
• Due to the complexity of the surgery, an estimated bypass 
time exceeding 100 min
• Preoperative pulmonary hypertension (defined by a 
mean pulmonary artery pressure greater than 25 mmHg 
at rest, with systolic pressure greater than 35 mmHg by 
echocardiography [20]) or a high risk of postoperative 
pulmonary hypertension (heart disease with pulmonary 
shunting).
Exclusion criteria were patients aged less than 28 days or 
more than 13 years, patients not meeting at least two of the 
above factors, refusal by the parents/guardians to participate 
in the study or refusal to provide informed consent, allergy 
or hypersensitivity to levosimendan or other components of 
 Simdax®, or patients to whom the study medication cannot 
be prescribed because it is contraindicated according to the 
technical data sheet, such as mechanical obstructions that 
affect ventricular filling or emptying or both, severe renal 
insufficiency (creatinine clearance [CrCl] < 30 ml/min), 
severe hepatic insufficiency, refractory arterial hypotension, 
and malignant arrhythmia (torsades de pointes). Excluded 
patients included those with a history of autoimmune disease 
and patients who were receiving inotropic infusions before 
surgery.
2.2  Settings
This clinical trial took place at the Virgen de las Nieves Uni-
versity Hospital in Granada, Spain. Patients were enrolled 
at the PICU, where levosimendan or placebo infusion was 
initiated 12 h before surgery. The infusion was continued in 
the operation room during the cardiopulmonary bypass and 
later when the patients came back to the PICU, where the 
infusion was maintained 24 h more.
2.3  Intervention
Patients were selected consecutively among those who met 
the inclusion criteria. On receipt of the corresponding signed 
informed consent forms, the patients were assigned to a spe-
cific treatment group (levosimendan or placebo) by a sim-
ple randomisation process, in which a succession of random 
numbers were generated using specialised software for this 
purpose (M.A.S. 2.1®, GlaxoSmithKline). This randomisa-
tion was performed by the hospital pharmacy service 24 h 
before the cardiopulmonary bypass.
In accordance with the study protocol, the levosimendan 
or placebo infusion was initiated 12 h before the cardiopul-
monary bypass procedure, continued during the surgery, and 
subsequently maintained for 24 h in the PICU.
The endpoints were assessed on arrival from the operat-
ing room and at 12 h and 24 h after postoperative admission. 
This last matched in time with the end of the levosimendan 
or placebo infusion.
The appropriate dosage of levosimendan, according to 
the drug package insert, is 0.05–0.2 µg/kg/min, with a prior 
loading dose of 6–12 µg/kg. Previous comparable studies 
of paediatric patients have used dosages of 0.1–0.2 µg/kg/
min, in most cases, also with a loading dose. However, in 
the present trial, it was decided not to administer the load-
ing dose, but rather to start perfusion at the maximum dos-
age recommended in the drug package insert. This dosage 
has been shown to be safe, and in the absence of a loading 
dose, the risk of hypotension or excessive vasodilatation is 
reduced [21]. After randomisation, the patients were given 
a continuous infusion of levosimendan or placebo from 12 
h before the surgery until 24 h afterwards (i.e. 36 h of treat-
ment), as described below:
• Experimental group: Levosimendan was supplied intra-
venously at a dosage of 0.2 µg/kg/min diluted in 5% 
glycated serum from 12 h before the surgery until 24 h 
after surgery (with no loading dose) (Levo, Anatomical 
Therapeutic Chemical [ATC] Classification group code 
C01CX: other cardiac stimulants; trade name:  Simdax®; 
presentation: 2.5 mg/ml; concentrate for infusion solu-
tion; pack with 5-ml vial; route of administration: intra-
venous).
• Placebo group: These patients received a continuous 
intravenous infusion of glucose serum at 5% (GS5%), 
prepared in opaque syringes identical in appearance and 
with the same volume as those used for the intravenous 
administration of levosimendan.
The intervention was masked to the investigator who 
assigned the treatment groups, to the patients’ parents/guard-
ians, and to the nurse who administered the intervention 
(observer). The Hospital Pharmacy Service was responsible 
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for supplying the intervention material and the placebo as 
individualised daily doses through dose drug dispensing sys-
tem. Identical syringes and opaque infusion systems were 
used in order to prevent visualisation of the drug’s colour 
(levosimendan is a yellow-orange solution). The systems for 
administration of the drug were received pre-purged (with 
1.5 ml of GS5%) to facilitate direct administration.
The intervention materials were labelled in accordance 
with the regulations set out in Annex 13 on the labelling 
of drugs used in clinical research, issued by the Spanish 
Agency of Medicines and Medical Devices. Following the 
cardiopulmonary bypass, patients in both groups received 
the additional inotropic treatment needed according to their 
individual haemodynamic situation, following the recom-
mendations for the management of the postoperative myo-
cardial dysfunction after cardiopulmonary bypass [4].
Regarding the potential adverse effects of levosimendan, 
it was decided that patients would be excluded from the 
study if any of the following situations arose: a serious 
adverse event, serious adverse reaction, a severe intercur-
rent disease, or the withdrawal of consent by the patient’s 
parents/guardians.
2.4  Endpoints of the Study
The primary endpoint of the study was at 24 h after surgery, 
when levels of troponin I and BNP were determined.
To date, no echocardiographic parameters have been 
validated for cardiac output monitoring in children, so the 
present assessment is based on the evaluation of multiple 
physiological parameters and analytical parameters such 
as lactate levels and central venous oxygen saturation [2]. 
However, troponin I is a sensitive and specific biomarker 
of myocardial injury after cardiopulmonary bypass and an 
independent predictor of postoperative myocardial dysfunc-
tion after congenital heart disease surgery in children [22].
Parameters such as the safety of levosimendan infusion 
in children, possible adverse effects during the intravenous 
infusion, the duration of mechanical ventilation, the length 
of stay in the PICU, and the 30-day mortality rate were 
addressed in the secondary study aims.
When patients were assigned to the corresponding study 
groups, the following demographic variables were collected: 
sex, age, weight, body surface area, surgically treatable con-
genital heart disease, Risk Adjustment for Congenital Heart 
Surgery (RACHS-1) score, prior pharmacological treatment 
with angiotensin-converting enzyme inhibitors, digoxin, or 
beta-blockers, and preoperative levels of BNP. After surgery, 
aortic clamping time, length of cardiopulmonary bypass 
(minutes), and modified ultrafiltration volume (millilitres) 
were recorded.
From the preoperative stage to 24 h after surgery, all 
patients were continuously monitored, and physiological 
variables such as heart rate, respiratory rate, central and 
peripheral temperature (rectum and foot, respectively), arte-
rial pressure, and pulse oximetry were recorded before start-
ing the study infusion.
Acid–base status, lactate levels, haemoglobin concentra-
tion, and BNP (pg/dl) were studied at the patient’s admission 
to the PICU. Intermediately after the surgical procedure and 
later at 12 and 24 h after the surgery, all these parameters 
were determined in addition to troponin I levels.
In addition, the following variables were measured when 
the patient was admitted to the PICU after the surgical pro-
cedure and at 12 and 24 h after the surgery: heart rate, mean 
arterial pressure (MAP; mmHg), central venous pressure 
(CVP; mmHg), thermal gradient (°C), capillary refill time 
(seconds), diuresis (ml/kg/h), creatinine (mg/dl), CrCl (ml/
min/1.73 m2), arrhythmia, vasoactive-inotropic index (VIS) 
score, central venous oxygen saturation (%), and oxygen 
delivery  (DO2) (ml/min/m2).
Prior to discharge from the PICU, data on length of stay 
(days), days of invasive mechanical ventilation required, 
appearance of complications and/or adverse effects, and the 
rate of survival at 30 days were collected.
2.5  Statistical Analysis
The sample size required for the study was calculated by 
reference to data obtained in previous research in this field. 
Regarding other study parameters, decreased BNP levels 
have been observed after levosimendan infusion in patients 
with acute heart failure, although without quantifying the 
difference versus placebo treatment. In contrast, other 
haemodynamic variables have been reported to improve. 
Thus, Magliola et al. [23] described a 50% improvement 
in the inotropic score and in the arteriovenous oxygen dif-
ference  (AVDO2) in patients with postoperative myocardial 
dysfunction after cardiopulmonary bypass when they were 
administered levosimendan versus patients who did not 
receive this treatment. Therefore, to detect differences in 
the test of the null hypothesis (H0) that p1 = p2 by a bilateral 
χ2 test for two independent samples, with a power of 0.8 and 
an error ∞ = 0.05, we calculated that 15 patients should be 
included in each group.
The study data were analysed using SPSS Statistics for 
Windows (version 19; IBM Corp., Armonk, New York, 
USA), according to intention to treat. The continuous vari-
ables are expressed as means and 95% confidence intervals 
(CIs) and the qualitative ones in terms of absolute and rela-
tive frequencies. The normality of the data distribution was 
determined by the Shapiro-Wilk test. Possible differences 
between the groups were identified by means of a bivariate 
analysis, applying Student’s t test for independent samples. 
For non-normal distributed variables, bootstrap simulation 
was performed to calculate the 95% CIs and the differences 
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in means. The qualitative variables were analysed using 
Pearson’s chi-square or Fisher’s exact test, and the continu-
ous variables by calculating the mean differences between 
the two groups and the corresponding 95% CIs. For the 
qualitative data, odds ratios (ORs) and 95% CIs were cal-
culated. Two-tailed P values less than 0.05 were considered 
statistically significant.
3  Results
During the study period (January 2013 to November 2016), 
30 patients were scheduled for paediatric cardiac surgery 
at the Virgen de las Nieves University Hospital. 15 (50%) 
received levosimendan and 15 (50%) received the placebo. 
The trial concluded in accordance with the date foreseen 
in the protocol presented to the Andalusian Progress and 
Health Foundation.
The demographic and baseline clinical characteristics of 
all patients are shown in Table 1. We are aware that we have 
included a heterogeneous population of patients due to the 
low prevalence of paediatric patients requiring cardiac sur-
gery nowadays. There were no statistically significant differ-
ences between the groups in terms of clinical characteristics 
prior to the intervention, pharmacological treatment, pre-
surgical BNP values, or RACHS-1 score. Table 2 is attached 
in order to describe each of the performed procedures in 
each study group. 
Two patients presented severely low cardiac output that 
caused the blinding to be suspended. Both patients were 
originally assigned to the placebo group, and when the 
blinding was suspended, they initiated levosimendan. One of 
these patients had three episodes of cardiorespiratory arrest, 
which were survived, and the other one required extracor-
poreal membrane oxygenation therapy. This second patient 
subsequently died of a cerebral haemorrhage.
Among all the patients in the treatment group, haemody-
namic tolerance to the administration of levosimendan was 
excellent, and it was not associated in any case with adverse 
effects that required suspension of the treatment. In fact, 
no patients in levosimendan group required suspension of 
blinding, extracorporeal membrane oxygenation therapy or 
heart transplantation. No patients of any group required a 
heart transplant.
Table 3 shows the results obtained for each study group 
(levosimendan vs. placebo), collected on admission to the 
PICU and at 12 and 24 h after the cardiopulmonary bypass 
procedure. Troponin I was higher in the placebo group at 0, 
12, and 24 h after cardiopulmonary bypass, although the dif-
ferences were not statistically significant. BNP levels were 
higher 12 and 24 h after cardiopulmonary bypass, although 
the differences were not statistically significant either.
Lactate levels were higher with the placebo at 0 and 12 
h after cardiopulmonary bypass, and significant differences 
were observed also with the  DO2 values, which were higher 
in the experimental group at 12 and 24 h after surgery. Fig-
ures 1, 2, 3, and 4 are attached in order to summarise part of 
the information shown in Table 3.
Our analysis of the other study parameters such as the 
VIS and of physiological variables such as CVP did not 
reveal statistically significant differences between the 
groups, although both parameters were higher with placebo 
at each of the three time points. Regarding the other physi-
ological variables analysed, there were no significant differ-
ences between the groups.
There were no statistically significant differences between 
the groups regarding the incidence of arrhythmia in the 
postoperative period (13.3% in the levosimendan group 
Table 1  Demographic and baseline clinical characteristics of the two 
groups of patients
Normal numerical variables are expressed as mean and standard devi-
ation, and the nonparametric variables as median [P25–P75]. Qualita-
tive variables are expressed in frequency and percentage
ACE angiotensin-converting enzyme inhibitors, BNP B-type natriu-
retic peptide, MUF modified ultrafiltration volume, PHT pulmonary 







Male/female, n (%) 9 (60)/6 (40) 10 (66.7)/5 (33.3) 0.705
Weight, kg 6 [5.1–13.5] 7 [5.2–13] 0.678
Height, cm 66 [63–100] 65 [61–92] 0.835
Age, years 0.6 [0.5–4] 0.9 [0.6–8] 0.517
Body surface area, 
 m2






7 (46.7) 3 (20) 0.121
 Beta-blockers, 
 n (%)
0 (0) 2 (13.3) 0.483
 Digoxin, n (%) 0 (0) 1 (6.7) 1
Preoperative PHT, 
n (%)
9 (60) 5 (33.3) 0.143
Preoperative BNP, 
pg/dl
104.5 [42.85–155.5] 32.5 [22.6–81] 0.063
 Corrective surgery, 
n (%)
15 (100) 14 (93.3) 1
 Bypass duration 
(min)
113 [95–130] 113 [106–154] 0.519
 Clamp duration 
(min)
77 [55–91] 85 [72–120] 0.329
 MUF, ml 416.67 ± 186.76 325.00 ± 224.07 0.248
 RACHS-1 2 [2, 3] 2 [2–2] 0.671
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and 13.3% in the control group; mean difference [95% CI] 
1 [0.12–8.21]; Table 4). This table also shows that for the 
duration of invasive mechanical ventilation and the length 
of stay in the PICU, there were no statistically significant 
differences between the groups. Regarding the outcome vari-
ables, 30-day survival was 100% in the levosimendan group, 
but 13.3% of the patients in the control group died during 
this period.
4  Discussion
Levosimendan may be advantageous in patients requiring 
inotropic support who are also at risk of myocardial ischae-
mia. Activation of adenosine triphosphate-regulated potas-
sium channels during infusion of levosimendan may produce 
cardioprotective effects while simultaneously enhancing 
ventricular contractile function. Experimental evidence 
indicates that  KATP-channel activation is the end-effector 
of a cardioprotective signal transduction pathway activated 
during ischaemic preconditioning. Levosimendan stimulates 
glyburide-sensitive  KATP-channel currents in ventricular and 
arterial myocytes, and this occurs independently of myofila-
ment  Ca2+-sensitising properties of this drug, hyperpolarises 
arterial smooth muscle cells in vitro, decreases intracellular 
calcium concentration, and relaxes coronary arteries inde-
pendently of intracellular calcium concentration. Levosi-
mendan increased coronary blood flow and increased sub-
epicardial and midmyocardial collateral perfusion at a dose 
that produces a concomitant positive inotropic effect [11].
In order to assess the haemodynamic effects of the pre-
operative infusion of levosimendan in paediatric patients 
scheduled for cardiopulmonary bypass surgery, we examined 
two cardiac biomarker profiles: troponin I and BNP levels. 
These parameters were determined at three time points dur-
ing the first 24 h after surgery. From the results obtained, we 
cannot conclude that levosimendan versus placebo reduces 
postoperative troponin I or BNP levels. Although both bio-
markers were higher at 12 and 24 h after surgery with the 
placebo, the differences were not statistically significant.
Previous studies have shown that BNP and N-terminal 
prohormone of brain natriuretic peptide (NT-proBNP), 
rather than being independent predictors of mortality in 
patients with heart failure, are in fact predictors of postop-
erative myocardial dysfunction [24]. In this respect, Parissis 
et al. reported a significant decrease in plasma BNP levels 
after the administration of levosimendan in patients with 
abnormal left ventricular diastolic function [25], and a recent 
meta-analysis concluded that levosimendan infusion in adult 
patients with acute heart failure appeared to reduce BNP, 
compared with placebo or furosemide [26].
According to prior research, the preoperative infusion 
of levosimendan reduces troponin I levels in the immedi-
ate postoperative period, although these results were not 
confirmed in our study. A prospective randomised study by 
Tritapepe et al. concluded that patients who received levo-
simendan before cardiopulmonary bypass surgery presented 
lower troponin I levels and had a significantly higher index 
of cardiac output than the control group [27]. These find-
ings were corroborated by Momeni et al., who performed 
the first randomised, double-blind, prospective study of 
paediatric patients undergoing cardiac surgery, to compare 
the intraoperative administration of levosimendan versus 
milrinone. These authors obtained similar results, reporting 
lower postoperative plasma troponin I levels in the patients 
who received intraoperative levosimendan [28].
Levosimendan treatment also failed to have any signifi-
cant impact on mortality and length of stay in the PICU, days 
of mechanical ventilation, or survival rates. Nevertheless, 
the survival rate was 100% with levosimendan, and none 
of these cases required suspension of the blinding, while 
with placebo, two patients presented a severe postoperative 
myocardial dysfunction, and it was necessary to suspend 
the blinding before 24 h after the cardiopulmonary bypass.
The patients in the levosimendan group did not present 
reduced MAP values, higher heart rate, or greater develop-
ment of arrhythmia at any time during follow-up. In fact, no 
adverse effects due to levosimendan infusion were observed.
Only limited information has been published about the 
proportions of paediatric patients experiencing side effects 
from the administration of levosimendan. In this respect, 
values ranging from 0% to 54% have been reported [24–26]. 
The prevalence of hypotension, one of the most danger-
ous side effects, has been estimated at 11–30% according 
Table 2  Procedures performed in each group
AoS subaortic stenosis resection, AV canal surgical correction of atrioventricular canal defects, CIA surgical correction of atrial septal defects, 
CIV surgical correction of ventricular septal defects, DO-RV surgical correction of double-outlet right ventricle, PVR total pulmonary vein 
repair, SMI surgical correction of mitral insufficiency, SPI surgical correction of pulmonary insufficiency, T. Fallot surgical correction of tetral-
ogy of Fallot
SMI CIV AV canal AV canal + 
T. Fallot
CIA + CIV T. Fallot CIV + 
DO-RV
SPI AoS PVR
Levosimendan (n = 15) 1 5 4 0 0 2 0 1 1 1
Placebo (n = 15) 3 2 2 1 2 3 2 0 0 0
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to retrospective studies [29]. Other adverse effects of 
levosimendan have been described as arrhythmia, dizzi-
ness, headache, insomnia, hypocalcaemia, anaemia, and 
gastrointestinal disorders. No fatal adverse effects have been 
reported [16].
Fig. 1  B-type natriuretic pep-
tide (BNP) levels obtained for 
each study group, collected on 
admission to the PICU and at 12 
h and 24 h after the cardio-
pulmonary bypass procedure. 
PICU paediatric intensive care 
unit BNP profile during first 
twenty-four hours after cardio-
pulmonary bypass procedure for 
each study group
Fig. 2  Troponin I levels 
obtained for each study group, 
collected on admission to the 
PICU and at 12 h and 24 h after 
the cardiopulmonary bypass 
procedure. PICU paediatric 
intensive care unit Troponin I 
profile during first twenty-four 
hours after cardiopulmonary 
bypass procedure for each study 
group
Fig. 3  Oxygen delivery  (DO2) 
levels obtained for each study 
group, collected on admis-
sion to the PICU and at 12 h 
and 24 h after the cardiopul-
monary bypass procedure. 
PICU paediatric intensive care 
unit DO2 profile during first 
twenty-four hours after cardio-
pulmonary bypass procedure for 
each study group
Levosimendan’s Effect on Biomarkers of Myocardial Injury After Paediatric Cardiac Surgery
Current evidence for the administration of levosimendan 
as a myocardial conditioner for adult patients remains slight, 
and this treatment is not recommended [30]. For children, 
even less research evidence is available about prophylactic 
levosimendan infusion as a pre-ischaemic myocardial condi-
tioner. Thus, a recent Cochrane meta-analysis evaluated only 
five clinical trials. Our study was cited in this meta-analysis, 
but not assessed because the outcome data had not yet been 
published [16]. It is important to note certain differences 
between our study and those included in the meta-analysis. 
On the one hand, none of the latter studied levosimendan 
versus placebo. On the other, our trial is the first to include 
the application of a conditioning protocol during the preop-
erative stage; other researchers have studied the administra-
tion of levosimendan initiated either intraoperatively or in 
the immediate postoperative period.
Analysis of other parameters related to the patients’ 
haemodynamic status suggests that ours may be a valuable 
approach. Significant differences were recorded between the 
lactate levels in each group, both on admission to the oper-
ating theatre and at 12 h after the cardiopulmonary bypass 
surgery. In addition,  DO2 levels at 12 and 24 h after surgery 
were statistically significantly higher with levosimendan 
than with the placebo. These results support those pub-
lished by Egan et al. [31] and Ricci et al. [32], both of whom 
reported a significant decrease in lactate levels with levosi-
mendan infusion. Moreover, these results are in line with 
those obtained in small-scale paediatric research, such as 
that performed by Osthaus et al. [33], who reported that 
while haemodynamic parameters such as heart rate, CVP, 
and MAP were not improved by levosimendan, there was a 
significant increase in venous oxygen saturation and a sig-
nificant decrease in lactate levels at 24 and 48 h after the 
start of the levosimendan infusion. This outcome is further 
evidence of the known inotropic effect of the drug.
The present study presents certain limitations that should 
be acknowledged. Although the clinical trial was randomised 
and double blinded, the number of patients was small. 
Moreover, no echocardiographic parameters were meas-
ured, because none had yet been validated for cardiac output 
monitoring in children, which is why the present assess-
ment is based exclusively on the evaluation of physiologi-
cal and analytical parameters. Finally, although no adverse 
effects of levosimendan infusion were recorded, the lack of 
statistical power of this study with regard to the safety of 
levosimendan should be taken into account. In consequence, 
Fig. 4  Lactate levels obtained 
for each study group, collected 
on admission to the PICU and at 
12 h and 24 h after the cardio-
pulmonary bypass procedure. 
PICU paediatric intensive care 
unit Lactate levels profile dur-
ing first twenty-four hours after 
cardiopulmonary bypass proce-
dure for each study group
Table 4  Results for invasive 
mechanical ventilation, duration 
of stay in PICU, and 30-day 
survival
Numerical variables are expressed as mean and 95% confidence interval (CI). Qualitative variables are 
expressed in frequency and percentage
PICU Pediatric intensive care unit





Mean diff. [95% CI]
Invasive mechanical 
ventilation (days)
4.06 [0.67–9.97] 3.02 [0.92–6.30] 1.05 [−4.14 to 7.41]
PICU (days) 10.73 [4.86–18.13] 8.27 [6.06–11.00] 2.47 [–4.24 to 10.42]
Post operative arrhyth-
mia (n)
2 (13.3%) 2 (13.3%) 1 [0.121 to 8.210]a
Exitus 0 (0%) 2 (13.3%) –
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further research in this area, with particular reference to the 
paediatric population, is needed to corroborate and extend 
the findings reported in this paper.
5  Conclusions
Levosimendan does not significantly influence the post-
operative cardiac biomarker profile during the immediate 
postoperative stage (troponin I and BNP levels) in com-
parison with placebo, though both biomarker levels were 
numerically higher with placebo after cardiopulmonary 
bypass. Levosimendan, however, significantly reduced lactic 
acid levels and improved patients’  DO2 profiles after sur-
gery. These results are indicative of the favourable effects 
of levosimendan on the cardiac muscle; however, we agree 
with other authors in this field that further research based 
on larger-scale, randomised, controlled trials is needed to 
enhance our understanding of the myocardial conditioning 
effect of levosimendan and its role in the complex manage-
ment of postoperative myocardial dysfunction in the paedi-
atric population.
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